Skip to Content

Multiple Myeloma: Belantamab Mafodotin plus Pomalidomide and Dexamethasone Show Significant Higher PFS, Deep Response and OS vs Those of Standard of Care

At the late-breaking oral session professor Meletios Dimopoulos presented the results from the randomized phase 3 DREAMM-8 study of the efficacy and safety of belantamab mafodotin plus pomalidomide and dexamethasone vs those of standard of care pomalidomide plus bortezomib and dexamethasone in patients with relapsed/refractory multiple myeloma previously treated with lenalidomide.

Meletios Dimopoulos

Få adgang

Hvis du er læge, sygeplejerske eller anden sundhedsprofessionel kan du få adgang til hele artiklen ved at oprette en profil på BestPractice Nordic.

Back to top